DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,705.00
+15.00 (0.41%)
At close: Aug 24, 2026

DongKoo Bio & Pharma Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
18,37221,56125,37215,71312,51419,557
Short-Term Investments
1,1371,107506.91,9411,351143.14
Trading Asset Securities
31,50212,49710,3715,24521,27112,399
Cash & Short-Term Investments
51,01135,16536,25022,89835,13632,100
Cash Growth
209.89%-3.00%58.31%-34.83%9.46%8.50%
Accounts Receivable
22,53419,34319,87619,87918,50315,774
Other Receivables
943.31253.081,3521,570898.47633.49
Receivables
26,33221,37023,95322,44919,40216,408
Inventory
36,24249,99645,96242,60631,42824,964
Prepaid Expenses
881.76450.63324.71216.61225.89229.66
Other Current Assets
3,08319,320751.62195.021,226131.5
Total Current Assets
117,550126,301107,24288,36587,41773,832
Property, Plant & Equipment
81,18177,44566,22250,48339,68140,051
Long-Term Investments
108,938121,47650,41939,80033,61935,498
Other Intangible Assets
5,5095,3865,46710,9039,0103,048
Long-Term Deferred Tax Assets
283.66-3,162291.56.95-
Long-Term Deferred Charges
2,7382,9377,705---
Other Long-Term Assets
2,3972,8053,8431,2602,3252,358
Total Assets
318,597336,350244,061191,103172,059154,786

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
6,8635,29115,59111,20214,30011,591
Accrued Expenses
11,4109,92011,33710,2749,6376,496
Short-Term Debt
95,406105,15674,87640,50033,00018,070
Current Portion of Long-Term Debt
2,717----5,000
Current Portion of Leases
580.83639.78681.03842.63567.83453.23
Current Income Taxes Payable
5,400390.963,3251,6382,5761,978
Other Current Liabilities
8,56916,0769,4418,8635,9636,434
Total Current Liabilities
130,946137,473115,25173,31866,04450,022
Long-Term Debt
23,20022,85210,4671,447--
Long-Term Leases
726.43134.07616.951,014754.22770.27
Pension & Post-Retirement Benefits
-00277.090205.81
Long-Term Deferred Tax Liabilities
798.026,7778.894.5140.932,315
Other Long-Term Liabilities
20,35016,95412,2694,5963,0151,350
Total Liabilities
176,021184,190138,61380,65869,95354,662

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
14,23214,23214,23214,23214,23214,232
Additional Paid-In Capital
33,51333,55533,06333,06333,06333,063
Retained Earnings
104,171114,06167,32069,73561,67557,158
Treasury Stock
-10,545-10,545-10,545-7,137-7,058-4,062
Comprehensive Income & Other
736.23398.211,261507.18193.39-266.18
Total Common Equity
142,108151,702105,332110,400102,106100,124
Minority Interest
468.77456.9116.0344.92--
Shareholders' Equity
142,576152,159105,448110,445102,106100,124
Total Liabilities & Equity
318,597336,350244,061191,103172,059154,786

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
122,630128,78286,64143,80434,32224,294
Net Cash (Debt)
-71,619-93,617-50,391-20,906813.887,806
Net Cash Growth
-----89.57%33.61%
Net Cash Per Share
-2579.40-3329.90-1856.67-756.8929.32276.23
Filing Date Shares Outstanding
27.0927.0427.0427.6127.6228.04
Total Common Shares Outstanding
27.0927.0427.0427.6127.6228.04
Working Capital
-13,396-11,173-8,00915,04621,37423,811
Book Value Per Share
5245.575609.853895.103998.843696.333570.78
Tangible Book Value
136,598146,31799,86599,49793,09697,076
Tangible Book Value Per Share
5042.215410.703692.933603.923370.163462.08
Land
15,86813,26213,26210,84910,84910,584
Buildings
38,61128,81527,61329,66727,35326,899
Machinery
8,2059,52012,45619,76817,74117,813
Construction In Progress
13,63321,2837,82310,6941,451887.9